Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
With the FDA’s approval of Novo Nordisk’s diabetes drug semaglutide for chronic weight management, the anti-obesity drug development community now has a chance to overcome the disappointments of its past.